Lupin Boss On Getting Biosimilar Manufacturing Right, Albuterol Outlook
Executive Summary
Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.
You may also be interested in...
Lupin’s ProAir Rival Has 'Moved Ahead' Despite CRL
Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.
US Setback For Lupin’s GxProAir But Application Has 'Moved Ahead'
Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.
Cipla Claims Pricing Advantage For Albuterol In US
Cipla, which expects to enter the US albuterol inhalation market later this year, believes that it has the cost competitiveness to price “significantly lower” than competition and take a “fair share” of a market that recently saw the arrival of authorized generics.